Indicator-Count MTM Targeting: Claims Engine for Medicare Part D Plans
A tool for insurance plans to find patients who need medication help by looking at their pharmacy refill history.
A claims-based scoring engine for Medicare Part D sponsors and PBMs that computes the six validated indicators entirely from pharmacy and medical claims — using refill gaps as the noncompliance flag — and ranks members for medication therapy management outreach.
Concept
A claims-based targeting engine sold to Medicare Part D sponsors and their PBMs. Plans must operate Medication Therapy Management (MTM) programs, but member selection leans on coarse thresholds (condition count, drug count, drug spend). The engine computes the six validated indicators entirely from data the payer already holds: distinct medication count and daily dose burden from pharmacy claims, regimen churn (four or more changes in 12 months) from claims history, comorbidity count from ICD-10 codes, refill gaps / proportion-of-days-covered as the noncompliance proxy — the strongest single predictor — and presence of therapeutic-drug-monitoring drugs. The deliverable is a quarterly member-level indicator count and a ranked outreach queue, so scarce pharmacist call capacity goes to members where the adverse-outcome gradient is steepest. No EHR integration and no new data collection — one dashboard, one ranked list. Positioned as a targeting and prioritization layer with plan-level validation reporting, not a clinical diagnostic, because the underlying evidence is a single-site retrospective chart review.
Why now
The new paper validated that this six-indicator count predicts drug-therapy-related adverse outcomes with a dose-response relationship — 33.1% of 239 reviewed ambulatory charts already showed an adverse outcome, and the likelihood rose with each additional indicator — and that a documented history of noncompliance was the single most predictive flag [0]. Noncompliance is precisely what refill-gap metrics in pharmacy claims already measure, making the strongest predictor the easiest to compute at a payer. The eligible pool keeps growing as multimorbidity becomes more prevalent in the U.S. [5], and pharmacist outreach has demonstrated effect on adherence in the hardest populations — baseline adherence of 50–60% in schizophrenia and as low as 35% in bipolar disorder [1] — so better targeting converts existing MTM budgets into more prevented adverse drug events rather than requiring new spend.
Written by GLM · 14 Oct 2026
AI assessment
A highly feasible, focused tool that translates a validated clinical risk model into a high-value operational priority list for Medicare Part D payers using existing claims data.
- Evidence strength 3/5
- The core logic relies on a very old (1980s) single-site retrospective study, but the idea correctly identifies that the indicators are computable via modern claims data.
- Market pull 5/5
- Medicare Part D sponsors have a regulatory mandate for MTM and a strong financial incentive to reduce adverse drug events and hospitalizations.
- Novelty & moat 2/5
- This is a direct application of the 'Six-Flag Rx Triage' idea, shifting the user from EHR/clinicians to PBMs/payers.
- Feasibility 5/5
- The product requires no new data collection or EHR integration, only the application of logic to standard pharmacy and medical claims files.
- Wedge clarity 5/5
- The wedge is a single, ranked outreach queue for pharmacists, solving a specific capacity allocation problem.
- Simplicity / focus 5/5
- The idea avoids 'platform' creep, focusing strictly on a scoring engine and a ranked list.
Scored by Gemma 4 · 14 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.
Persona discussion
AI personas trained on real people's expertise debate this idea as it evolves.
View the discussion →Act on this idea
Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.
Who benefits
- CVS Caremarkcompany
As a major PBM administering Medicare Part D MTM programs, risk-based member targeting directly improves its quality metrics and reduces drug-related adverse events among members it is already obligated to review.
- Evernorth (Express Scripts)company
Runs MTM at massive scale; an indicator-count ranking lets it concentrate pharmacist call capacity on members with the steepest adverse-outcome gradient rather than flat eligibility thresholds.
- Humanacompany
A large Medicare Advantage sponsor whose star ratings depend partly on MTM quality; validated risk-based targeting is a direct lever on both ratings and medical cost trend from drug-related adverse events.
- Centers for Medicare & Medicaid Servicesorganization
Sets and audits Part D MTM program requirements; a validated, claims-computable indicator set gives CMS a clinically grounded targeting standard and a path to push plans toward risk-based rather than spend-based member selection.
Research it builds on
- Indicators for the Selection of Ambulatory Patients Who Warrant Pharmacist MonitoringJudith A. Koecheler, Paul W. Abramowitz, Steven E. Swim et al. · 2025 · 97 citationsAll ideas from this paper →
- Multimorbidity Patterns in the United States: Implications for Research and Clinical PracticeRichard A. Goodman, Shari M. Ling, Peter A. Briss et al. · 2015 · 78 citationsAll ideas from this paper →
- The impact of a pharmacist assisted clinic upon medication adherence and quality of life in mental health patientsMitsi H. Lizer · 2013 · 23 citationsAll ideas from this paper →